IFPMA recognizes the work underway at the local and regional level, both within IFPMA member associations and various non-governmental organizations. Thus, the objective of this Note for Guidance is to complement existing work, and to provide additional interpretation and guidance on the provisions of Article 11 of the IFPMA Code of Practice (Interactions with Patient Organizations).
Read moreThis year’s theme for the International Women’s Day is “Each for Equal”. In an effort to showcase the crucial role women play in healthcare, we had the pleasure to speak with Margaret Afriyie, a midwife from Ghana, among others, about her efforts to empower women in rural communities to seek antenatal and postnatal care in...
Read moreThis article was originally published in French in AGEFI on March 3, 2020. Before it first emerged in December, the COVID-19 virus was unknown. Just a month later, the sharing of this new virus’s genome within the scientific community swiftly enabled researchers to set in train the initial stages of research and development (R&D) designed...
Read moreCOVID-19: An Unprecedented Mobilization of the Scientific Community On Thursday, 26 February 2020, Thomas Cueni spoke to Suisse media (RTS La Matinale). He explains how the innovative biopharmaceutical member companies of IFPMA are already helping and are taking practical steps to engage. Those companies with potentially relevant knowhow have teams of scientists checking their libraries...
Read moreAt WHO’s February Executive Board, The Global Self-Care Federation was among the UHC2030 Private Sector players to submit a statement. The statement calls for governments and other stakeholders to create an enabling environment for effective and structured private sector engagement, to accelerate progress on universal health coverage (UHC). Judy Stenmark, Director General of The Global Self-Care...
Read moreIFPMA and WHO Global Research and Innovation Forum IFPMA as the body representing the innovator biopharmaceutical industry in official relations with the UN, together with a number of its member companies were invited to the WHO Global Research and Innovation Forum on COVID-19 which took place on 11 and 12 February 2020 in Geneva. IFPMA...
Read moreThis article was originally published on Health Policy Watch on February 10, 2020. “We all have a vested interest to stop this epidemic,” says Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). As WHO on Tuesday convenes a Global Research & Innovation Forum to rapidly ramp up R&D, Cueni spoke with Health...
Read moreGeneva, February 10, 2020: Throughout the R&D-based biopharmaceutical industry, our first thoughts are with all those affected by the outbreak of the novel coronavirus (nCov-2019). The spread of the epidemic is a major public health threat for all affected countries; and we share the WHO’s concern for those countries with weaker health systems who could...
Read moreThis Statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association, and the Global Self-Care Federation (previously called the World Self-Medication Industry).
Read moreGeneva, 7 February, 2020: IFPMA welcomes the holistic approach of WHO to influenza preparedness, as well as the call for suggestions for further sensitizing Member States to the importance of timely influenza virus sharing, and for ways to promote influenza prevention and control strategies, including through the use of seasonal vaccination. We are concerned that...
Read more